Our technology is technically validated and currently moving towards a number of pre-clinical studies with a range of different compounds and vaccines. We are actively seeking collaborations with companies who are looking to enhance delivery of their injectables – be they existing compounds or vaccines on the market, generics looking to differentiate, or new compounds or vaccines looking to deliver intradermally. This can be areas such as small molecules, vaccines or biologics.
COVID 19 Partnerships
Pharma Latch offers a myriad of advantages for COVID 19 vaccine delivery. These include:
- Highly user centric facilitating self-administration
- Facilitates global, remote reach
- Compatible with any SARS-CoV-2 Antigen, mRNA, DNA etc.
- Intradermal delivery providing enhanced immune response
- Stable coating methodology removing cold chain and logistics requirements
- Low cost of goods and highly scalable manufacturing